Inhibrx Biosciences Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Feb '26 Feb 24, 2026	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Market Capitalization	1,156	223	-	-	-
Enterprise Value	1,110	28	-	-	-
Last Close Price	79.50	15.40	-	-	-
PE Ratio	-	0.13	-	-	-
PS Ratio	825.88	1114.65	-	-	-
PB Ratio	31.30	1.67	-	-	-
P/TBV Ratio	31.39	1.67	-	-	-
EV/Sales Ratio	792.89	142.16	-	-	-
Debt / Equity Ratio	2.90	0.06	4.83	-0.69	1.35
Net Debt / Equity Ratio	-1.25	-1.08	-1.56	-0.69	-1.16
Net Debt / EBITDA Ratio	0.24	0.55	0.31	-0.04	-
Net Debt / FCF Ratio	0.32	0.73	0.34	-0.05	-
Asset Turnover	0.01	0.00	0.01	0.02	-
Inventory Turnover	55.38	34.28	35.84	-	-
Quick Ratio	4.28	3.76	4.95	0.01	5.85
Current Ratio	4.49	3.94	5.25	0.30	6.20
Return on Equity (ROE)	-144.07%	1905.92%	-1333.38%	-511.61%	-
Return on Assets (ROA)	-60.97%	-67.38%	-84.42%	-86.27%	-
Return on Capital Employed (ROCE)	-137.90%	-188.10%	-87.10%	2794.40%	-59.80%
Earnings Yield	-13.41%	757.00%	-	-	-
FCF Yield	-12.41%	-88.37%	-	-	-
Buyback Yield / Dilution	-6.72%	-27.17%	70.62%	-5.52%	-

Updated Nov 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q